背景:性传播感染(STIs)如衣原体,淋病,梅毒,滴虫和滴虫对全球发病率和死亡率有重要贡献。研究人员正在寻找这些性传播感染的疫苗,目前正在进行衣原体疫苗的临床试验。然而,关于个人愿意接受衣原体的研究很少,淋病,梅毒,和滴虫病疫苗。本分析的目的是绘制我们现有的关于个人愿意接受这些细菌/寄生虫性性传播感染疫苗的文献,并了解仍需要哪些疫苗可接受性信息。
方法:我们检索了七个关于性传播感染疫苗可接受性的文献数据库,然后进行标题/摘要和全文审查,以评估资格。所有的评论和摘要都是由两名审稿人盲目进行的,与通过讨论或第三位审阅者的输入解决的差异。
结果:原始2,259篇感兴趣的文本中有8篇符合纳入标准。数据抽象后,我们发现淋病是最常检查的,其次是衣原体和梅毒。未报道毛滴虫病疫苗的可接受性。大多数文本报告了很高的可接受性,但似乎没有数据描述疫苗特性如何影响可接受性.同样,虽然文献涵盖了各种各样的人群,大多数研究人群来自美国或加拿大,他们是医疗机构的赞助人或来自大型健康干预研究的参与者.因此,需要更多关于北美以外人口的信息,以及医疗保健获取和利用率较低的群体。
结论:随着细菌和寄生虫性性传播感染的发病率增加,随着我们越来越接近这些疾病的疫苗,了解公众接受和接受这些疫苗的可能性对他们的成功至关重要。虽然现有文献描述了STI疫苗在各种人群中的可接受性,他们的总数很小。北美以外对STI疫苗可接受性的更多研究,特别是检查剂量数量等因素,定时,和成本影响疫苗的可接受性需要确保有效的未来疫苗推广。
BACKGROUND: Sexually transmitted infections (STIs) like chlamydia, gonorrhea, syphilis, and trichomoniasis contribute significantly to global morbidity and mortality. Researchers are pursuing vaccines for these STIs, and a clinical trial is currently underway for a chlamydia vaccine. However, there is little research available on individuals\' willingness to receive chlamydia, gonorrhea, syphilis, and trichomoniasis vaccines. The purpose of this analysis was to map the existing literature we have on individuals\' willingness to receive these bacterial/parasitic STI vaccines and understand what information on vaccine acceptability is still needed.
METHODS: We searched seven databases for literature on STI vaccine acceptability, then conducted title/abstract and full-text reviews to assess eligibility. All reviews and abstractions were conducted blindly by two reviewers, with discrepancies settled by discussion or the input of a third reviewer.
RESULTS: Eight of the original 2,259 texts of interest met inclusion criteria. After data abstraction, we found that gonorrhea was the most commonly examined, followed by chlamydia and syphilis. Trichomoniasis vaccine acceptability was not reported. Most texts reported high acceptability, but there did not appear to be data describing how vaccine characteristics affect acceptability. Similarly, while the literature covers a variety of populations, most of the study populations were based out of the United States or Canada and were patrons of healthcare facilities or participants from a larger health intervention study. Therefore, more information is needed on populations outside North America, and on groups with lower healthcare access and utilization.
CONCLUSIONS: As the incidence of bacterial and parasitic STIs increase, and as we grow nearer vaccines for these illnesses, understanding how likely the public is to accept and receive these vaccines is crucial to their success. While the existing literature describes STI vaccine acceptability in a variety of populations, their overall number is small. More research into STI vaccine acceptability outside of North America, and especially examining how factors like number of doses, timing, and cost influence vaccine acceptability is needed to ensure effective future vaccine rollouts.